Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06675357 · ClinicalTrials.gov registry record · Phase 2
Using FAPI PET/MRI to Evaluate Prostate Cancer
A Phase 2 study of Prostate Cancer Metastatic Disease and Prostate Cancers, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06675357: Recruiting Phase 2 study of Prostate Cancer Metastatic Disease and Prostate Cancers, sponsored by University of Wisconsin, Madison.
NCT06675357 is a Phase 2 study of Prostate Cancer Metastatic Disease and Prostate Cancers that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 30 participants, below the 49-participant average among 5 other Prostate Cancer Metastatic Disease trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06675357, a Phase 2 study of Prostate Cancer Metastatic Disease and Prostate Cancers, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Primary Outcome
Sensitivity and specificity for lesion detection on FAPI will be compared with that of PSMA PET, using a composite reference standard (all available histology, follow up clinical/standard of care imaging, serum PSA).
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- RADIATION FAPI
- PROCEDURE Positron Emission Tomography (PET)
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT06675357 shows while recruiting
NCT06675357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 49-participant average among 5 other Prostate Cancer Metastatic Disease trials with a reported enrollment target (39% lower).
The record links to 2 conditions, with Prostate Cancer Metastatic Disease appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT06675357 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06675357 about?
NCT06675357 is a clinical study titled "Using FAPI PET/MRI to Evaluate Prostate Cancer". The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants...
What is the current status of trial NCT06675357?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-02-27. Estimated completion is 2027-01.
What conditions does trial NCT06675357 study?
This clinical trial studies the following conditions: Prostate Cancer Metastatic Disease, Prostate Cancers.
What interventions are being tested in trial NCT06675357?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), FAPI (RADIATION), Positron Emission Tomography (PET) (PROCEDURE).
Who is sponsoring clinical trial NCT06675357?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06675357 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer Metastatic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection
RECRUITING · Phase 2
-
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
RECRUITING · Phase 2
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Role of Race in Nutritional Approach in Men on ADT
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI